Compare PK & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | ADMA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2014 | 2012 |
| Metric | PK | ADMA |
|---|---|---|
| Price | $11.04 | $7.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $11.22 | ★ $25.67 |
| AVG Volume (30 Days) | 4.2M | ★ 6.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.05 | ★ 0.19 |
| Revenue | ★ $2,791,000,000.00 | $42,219,783.00 |
| Revenue This Year | $2.40 | $27.46 |
| Revenue Next Year | $2.76 | $22.11 |
| P/E Ratio | $226.30 | ★ $43.03 |
| Revenue Growth | 2.35 | ★ 43.85 |
| 52 Week Low | $9.84 | $7.21 |
| 52 Week High | $12.39 | $22.37 |
| Indicator | PK | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 23.22 |
| Support Level | $10.85 | $7.21 |
| Resistance Level | $11.79 | $16.30 |
| Average True Range (ATR) | 0.34 | 0.55 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 12.70 | 10.76 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.